My Prognosis


C9081

Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Terminated December 31, 2021.

Notice
Short Description
HCPCS Coverage Code
HCPCS Action Code
HCPCS Action Effective Date
HCPCS Code Added Date
HCPCS Termination Date
HCPCS Pricing Indicator Code
HCPCS Multiple Pricing Indicator Code
HCPCS Statute Number
HCPCS Cross Reference Code
HCPCS Type Of Service Code
HCPCS Anesthesia Base Unit Quantity